Emirati rehabilitation specialist Cambridge Medical and Rehabilitation Centre (CMRC) has opened its first facility in Saudi Arabia. We speak to the group's CEO about the move.
Aster DM has reported strong top-line growth in its FY19 results and plans more asset-light projects in India going forward. We speak to the company's head of investor relations and take a look at how the company faired.
Dubai-based TVM Capital Healthcare has invested in a joint venture with a Ukrainian group whose founder pioneered a method of cerebral palsy rehabilitation. It is not the first Middle Eastern player to splash on East European rehab expertise.
Saudi Arabia's Ministry of Health is looking for more international operators to provide dialysis services across the Kingdom, despite having recently renewed contracts with Diaverum and DaVita. Local sources tell HBI that the Ministry wants international operators to help fill the supply gap in the Kingdom. The number of patients needing dialysis is expected to […]
Revenue at International healthcare group NMC breached $2bn for the first time in FY2018. The company repeated its 2019 guidance today (Thursday, March 7)- but its share price plummeted 9% as investors appeared to be cashing in.
Arab Health never seems to get any smaller. HBI travelled to Dubai and spoke to some of the 84,500 attendees and 4,150 exhibiting companies. But, strip out the hoop-la, and what is really going on at ground level? Here are our main takeaways from the four-day long event:
Two of Europe’s biggest healthcare companies which were widely expected to IPO imminently are now, we hear, ruling out this year. Why the delay – and what does this tell us about the state of a slowing market? HBI speaks to an operator CEO and investment banking sources.
Global dialysis operators Diaverum and Davita have renewed their contracts with the Saudi Ministry of Health for another five years. The deal leaves Diaverum free to proceed with its plans to IPO / go forward to a private sale and comes in the same week as a new portable dialysis device had its US market entry fast-tracked by the FDA. Is it a threat?
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
